CEL SCI CORP — Investor Relations & Filings
CEL-SCI Corporation is a clinical-stage biotechnology company engaged in the research and development of immunotherapies for cancer, autoimmune, and infectious diseases. Its lead investigational therapy, Multikine (Leukocyte Interleukin, Injection), is a neoadjuvant treatment designed to stimulate a patient's immune system to fight cancer before standard treatments like surgery, radiation, and chemotherapy are administered. The company has completed a global pivotal Phase III clinical trial for Multikine in patients with advanced primary, previously untreated squamous cell carcinoma of the head and neck. The study demonstrated a significant 5-year overall survival benefit in a specific patient subgroup. CEL-SCI is also developing its LEAPS (Ligand Epitope Antigen Presentation System) technology platform for potential treatments of autoimmune and infectious diseases.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| FORM 8-K | 2026-05-14 | English | |
| 8-K - CEL SCI CORP (0000725363) (Filer) | 2026-05-13 | English | |
| 424B4 | 2026-05-13 | English | |
| Regulatory Filings 2026 | 2026-05-12 | English | |
| S-1/A - CEL SCI CORP (0000725363) (Filer) | 2026-05-01 | English | |
| DEL AM | 2026-04-24 | English |
Browse filings by year
17 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
12 filings
| |||||
| 46274090 | FORM 8-K | 2026-05-14 | English | ||
| 45766521 | 8-K - CEL SCI CORP (0000725363) (Filer) | 2026-05-13 | English | ||
| 46081758 | 424B4 | 2026-05-13 | English | ||
| 46081745 | Regulatory Filings 2026 | 2026-05-12 | English | ||
| 39639190 | S-1/A - CEL SCI CORP (0000725363) (Filer) | 2026-05-01 | English | ||
| 46081761 | DEL AM | 2026-04-24 | English | ||
| 34662842 | S-1 - CEL SCI CORP (0000725363) (Filer) | 2026-04-17 | English | ||
| 32880286 | 10-Q - CEL SCI CORP (0000725363) (Filer) | 2026-02-17 | English | ||
| 18269065 | 4 Filing | 2026-01-26 | English | ||
| 18269090 | 4 Filing | 2026-01-05 | English | ||
| 18269058 | 4 Filing | 2026-01-05 | English | ||
| 18269037 | 4 Filing | 2026-01-05 | English | ||
|
2025
3 filings
| |||||
| 18269100 | 10-K Filing | 2025-12-29 | English | ||
| 9417629 | PRIMARY DOCUMENT | 2025-12-05 | English | ||
| 9417630 | Regulatory Filings 2025 | 2025-12-04 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Protagenic Therapeutics, Inc.\new
Develops peptide-based therapeutics for stress-related neur…
|
PTIX | US | Professional, scientific and te… |
|
Protara Therapeutics, Inc.
Clinical-stage biopharma developing therapies for cancer an…
|
TARA | US | Professional, scientific and te… |
|
PROTEINA CO.,LTD.
A biotech firm analyzing protein interactions for drug and …
|
468530 | KR | Professional, scientific and te… |
|
PROTEOME SCIENCES PLC
A Contract Research Organization focused on applied proteom…
|
PRM | GB | Professional, scientific and te… |
|
PROTEOMICS INTERNATIONAL LABORATORIES LTD
Develops proteomic diagnostics and provides analytical serv…
|
PIQ | AU | Professional, scientific and te… |
|
PROTHENA CORP PUBLIC LTD CO
Biotechnology company developing therapies for diseases of …
|
PRTA | US | Professional, scientific and te… |
|
PROVEXIS PLC
Develops and licenses functional ingredients for the food a…
|
PXS | GB | Professional, scientific and te… |
|
PR Technology Inc.
Specializes in low-frequency resonant Wireless Power Transm…
|
PRTI | CA | Professional, scientific and te… |
|
Psomagen, Inc.
A contract lab providing multiomics and data analysis solut…
|
950200 | US | Professional, scientific and te… |
|
Psych Capital Plc
Biopharmaceutical company developing psilocybin-based thera…
|
PSY | GB | Professional, scientific and te… |
CEL SCI CORP via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34401/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34401 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34401 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34401 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34401}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for CEL SCI CORP (id: 34401)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.